If you follow weight-loss medicine, you have probably seen retatrutide described as the next big thing. It is genuinely promising — but it is also still in clinical trials. Tirzepatide, by contrast, is here today. Here is an honest comparison.
The quick answer
Tirzepatide is a dual-hormone medication that activates two gut-hormone receptors: GIP and GLP-1. It is FDA-approved and is the active molecule in widely used branded products. You can start a doctor-guided tirzepatide program now.
Retatrutide is an investigational triple-hormone medication that adds a third target — glucagon — to the GIP and GLP-1 pair. It is not FDA-approved and is only available through clinical trials [4]. Nothing below should be read as an offer for retatrutide; it is included for education only.
What the trials show
In its pivotal obesity trial (SURMOUNT-1), once-weekly tirzepatide produced mean weight reductions of roughly 15% to 21% over 72 weeks depending on the dose, compared with about 3% on placebo [1].
In an earlier-stage, 48-week phase 2 trial, retatrutide produced a mean weight reduction of about 24% at its highest dose, versus about 2% on placebo [2]. That number is striking — but it comes from a smaller, dose-finding study, not a confirmatory phase 3 trial, and direct head-to-head comparisons between the two drugs have not been published.
| Tirzepatide | Retatrutide | |
|---|---|---|
| Hormone targets | GIP + GLP-1 (dual) | GIP + GLP-1 + glucagon (triple) |
| FDA status | Approved | Investigational (in trials) |
| Evidence stage | Phase 3 + real-world use | Phase 2 (dose-finding) |
| Available through Bon | Yes (compounded) | No |
How to read the difference
A bigger number in an earlier trial is not the same as a better, safer, available treatment. Phase 2 results often shift once larger phase 3 trials report full efficacy and safety. Tirzepatide has years of phase 3 data and real-world experience behind it.
Both drug classes share a similar side-effect profile — mostly gastrointestinal, mostly during dose titration [3]. We cover that in detail in our guide to managing GLP-1 side effects.
The bottom line
If you want to start now, tirzepatide is the evidence-backed, available option. Retatrutide is worth watching, but it is not something you can or should obtain outside a trial today.
Bon Health offers doctor-guided compounded tirzepatide from $170/month — $0 membership, prescribed and dosed by a licensed physician after a medical review.
This article is for general education and is not medical advice. It does not replace the judgment of a licensed clinician. Compounded medications are not FDA-approved. Always talk with your healthcare provider before starting, changing, or stopping any medication.